Insulet (PODD) vs Teleflex (TFX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teleflex (TFX) has outperformed Insulet (PODD) over the past year, losing 1.9% versus a loss of 57.1%. Over five years, PODD leads with a -55.3% price change compared with -65.7% for TFX. Insulet is the larger company by market cap ($9.26 billion vs $5.21 billion), about 1.8 times the size.
On valuation, Teleflex trades at a lower forward P/E (11.2x vs 17.3x for Insulet). Teleflex pays a dividend yielding 1.11%, while Insulet does not currently pay one. Insulet converts more of its revenue into profit, with a net margin of 9.1% versus -45.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PODD | TFX |
|---|---|---|
| Share price | $133.46 | $122.84 |
| Market cap | $9.26B | $5.21B |
| 1-day change | -0.67% | -1.32% |
| YTD return | -52.73% | +2.00% |
| 1-year return | -57.14% | -1.90% |
| 5-year return | -55.29% | -65.73% |
| P/E ratio (TTM) | 24.99 | — |
| Forward P/E | 17.26 | 11.22 |
| EPS (TTM) | $5.34 | $-8.48 |
| Dividend yield | 0.00% | 1.11% |
| Annual dividend | $0.00 | $1.36 |
| Revenue (latest FY) | $2.71B | $1.99B |
| Revenue growth (YoY) | +30.73% | +17.25% |
| Net income (latest FY) | $247.10M | $-905.64M |
| Gross margin | 71.63% | 56.24% |
| Operating margin | 17.50% | 5.94% |
| Net margin | 9.12% | -45.45% |
| 52-week high | $354.88 | $145.00 |
| 52-week low | $126.40 | $100.18 |
| Distance from 52-week high | -62.39% | -15.28% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +28.10% | +25.96% |
| Average volume | 1.68M | 655.00K |
| Shares outstanding | 69.35M | 42.37M |
| Employees | 5,400 | 15,500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TFX has outperformed PODD by 55.2 percentage points over the past year.
- Teleflex offers a meaningfully higher dividend yield (1.11% vs 0.00%).
- Insulet is more profitable, keeping 9.1 cents of every revenue dollar as net income versus -45.4 cents for Teleflex.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +17.25%).
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
About Teleflex
TFX stock →Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand.
Health Care · Medical/Dental Instruments · 15,500 employees
PODD vs TFX FAQ
Which is bigger, Insulet or Teleflex?
Insulet (PODD) is larger, with a market capitalization of $9.26B compared with $5.21B for Teleflex (TFX).
Which stock has performed better over the past year, PODD or TFX?
TFX returned -1.90% over the past 12 months, compared with -57.14% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Insulet or Teleflex?
Teleflex pays a dividend yielding 1.11%, while Insulet does not currently pay a regular dividend.
Are Insulet and Teleflex in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.